.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,993,750

« Back to Dashboard

Details for Patent: 8,993,750

Title:5HT.sub.2C receptor modulators
Abstract: The present invention relates to novel compounds of Formula (I): ##STR00001## which act as 5HT.sub.2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Inventor(s): Smith; Brian (San Diego, CA), Smith; Jeffrey (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Jul 09, 2014
Application Number:14/326,977
Claims:1. A process for preparing a compound of Formula H ##STR00060## wherein R.sub.1 is H, and R.sub.2 is chosen from H, Br, Cl, and I, said process comprising the step of: deprotecting a compound of Formula G to form a compound of Formula H.

2. The process of claim 1, further comprising the step of: forming a pharmaceutically acceptable salt of a compound of Formula H.

3. The process of claim 1, further comprising the step of: preparing a composition comprising a compound of Formula H.

4. The process of claim 2, further comprising the step of: preparing a composition comprising a pharmaceutically acceptable salt of a compound of Formula H.

5. A process for preparing 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine comprising the step of: deprotecting N-trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine to form 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

6. The process of claim 5, wherein the N-trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is prepared by a process comprising the step of: hydrogenating N-trifluoroacetyl-8-chloro-1-methylene-2,3,4,5-trihydro-1H-3-benzazepine.

7. The process of claim 6, wherein the N-trifluoroacetyl-8-chloro-1-methylene-2,3,4,5-trihydro-1H-3-benzazepine is prepared by a process comprising the step of: reacting N-allyl, N-trifluoroacetyl-2-iodo-4-chlorophenethylamine under conditions suitable for forming N-trifluoroacetyl-8-chloro-1-methylene-2,3,4,5-trihydro-1H-3-benzazepine.

8. The process of claim 5, further comprising the step of: forming a pharmaceutically acceptable salt of the 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

9. The process of claim 5, further comprising the step of: preparing a composition comprising the 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

10. The process of claim 8, further comprising the step of: preparing a composition comprising a pharmaceutically acceptable salt of the 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

11. A process for preparing a pharmaceutically acceptable salt of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine comprising the steps of: dissolving 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine in a suitable solvent containing a pharmaceutically acceptable acid, and isolating the pharmaceutically acceptable salt of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

12. The process of claim 11, further comprising the step of: preparing a composition comprising a pharmaceutically acceptable salt of the 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

13. A process for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine comprising the steps of: providing 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, wherein the amine nitrogen is optionally protected; separating (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, wherein the amine nitrogen is optionally protected, from (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, wherein the amine nitrogen is optionally protected, using chiral chromatography.

14. The process of claim 13, wherein the amine nitrogen of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is protected and the process further comprises the step of: deprotecting the amine nitrogen of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

15. The process of claim 14, further comprising the step of: forming a pharmaceutically acceptable salt of the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

16. The process of claim 14, further comprising the step of: preparing a composition comprising the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

17. The process of claim 15, further comprising the step of: preparing a composition comprising a pharmaceutically acceptable salt of the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

18. The process of claim 13, wherein the amine nitrogen of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is not protected, and the process further comprises the step of: preparing a composition comprising the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

19. The process of claim 13, wherein the amine nitrogen of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is not protected, and the process further comprises the step of: forming a pharmaceutically acceptable salt of the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

20. The process of claim 19, further comprising the step of: preparing a composition comprising a pharmaceutically acceptable salt of the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc